화학공학소재연구정보센터
Applied Chemistry for Engineering, Vol.30, No.3, 303-307, June, 2019
락톤형 소포로리피드의 물리화학적 특성 및 항균효과
Physico-chemical Properties and Antibacterial Activities of Lactonic Sophorolipid
E-mail:
초록
소포로리피드(sophorolipid)는 Candida bombicola에 의해 생산되는 당지질 구조의 생물 계면활성제로, 일반적으로 산성형과 락톤형의 혼합으로 존재한다. 본 연구에서는 소포로리피드 생산균주의 유전자조절과 대사공학적 방법을 통해 락톤형이 96% 이상으로 존재하는 소포로리피드의 물리화학적 특성, 항균 특성, 세포독성 등을 살펴보았다. 락톤형 소포로리피드를 물에 1 wt%에서 0.001 wt% 농도로 희석시키면 pH가 3.2~4.6 범위의 약산성을 나타내었다. 산-염기 적정곡선으로부터 락톤형 소포로리피드의 pKa 값은 대략 4.3으로 측정되었다. 임계 마이셀 농도(CMC)는 10-2 wt%로, 이때 수용액의 표면장력은 36 mN/m까지 감소하였다. 락톤형 소포로리피드의 항균 활성을 살펴본 결과, Propionibacterium acnes에 대하여 1 × 10-3 g/mL, Corynebacterium xerosis에 대하여 5 × 10-3 g/mL의 최소저지농도(MIC) 값을 보였다. MTT assay 실험 결과로부터 락톤형 소포로리피드의 세포독성이 트리클로산보다 10배 더 낮은 것으로 나타났다.
Sophorolipid is a biological surfactant of the glycolipid structure produced by Candida bombicola, which generally exists as a mixture of acidic and lactonic forms. In this study, we investigated physico-chemical properties, antibacterial activities, and cytotoxicity of the sophorolipid containing more than 96% of the lactonic form, produced by the gene regulation of production strains and application of a metabolic engineering technique. The lactonic sophorolipid showed a weak acidity in the range of pH 3.2~4.6 when diluted in water at the concentrations from 1 to 0.001 wt%. The pKa value of the lactonic sophorolipid was estimated to be around 4.3 from the acid-base titration curve. The critical micelle concentration (CMC) of the lactonic sophorolipid was 10-2 wt%, at which the surface tension of aqueous solution was reduced to 36 mN/m. The lactonic sophorolipid showed the minimum inhibitory concentrations (MIC) of 1 × 10-3 and 5 × 10-3 g/mL against Propionibacterium acnes and Corynebacterium xerosis, respectively. The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay showed that cytotoxicity of the lactonic sophorolipid was ten times lower than that of triclosan.
  1. Gorin PAJ, Spencer JFT, Tulloch AP, Torulopsis magnoliae. Can. J. Chem., 39, 846 (1961)
  2. Van Bogaert INA, Zhang JX, Soetaert W, Process Biochem., 46(4), 821 (2011)
  3. Hirata Y, Ryu M, Oda Y, Igarashi K, Nagatsuka A, Furuta T, Sugiura M, J. Biosci. Bioeng., 108(2), 142 (2009)
  4. Gudina EJ, Rangarajan V, Sen R, Rodrigues LR, Trends Pharmacol. Sci., 34, 667 (2013)
  5. de Oliveira MR, Magri A, Baldo C, Camilios-Neto D, Minucelli T, Celligoi MAPC, Int. J. Adv. Biotechnol. Res., 6(2), 161 (2015)
  6. Develter D, Renkin M, Jacobs I, Eur. Patent 01445302 (2006).
  7. Marchal R, Lemal J, Sulzer C, Davila AM, US Patent 5,900,366 (1999).
  8. Furuta T, Igarashi K, Hirata Y, World Patent 03/002700 (2003).
  9. Sohn HY, Kim YS, Kim EJ, Kwon YS, Son KH, Korean J. Microbiol. Biotechnol., 34, 265 (2006)
  10. Ha MH, Cho SH, Propionibacterium acnes, Asian J. Beauty Cosmetol., 2(3), 69-75 (2004).
  11. Choi SM, Kim MJ, Choi YH, Ahn HJ, Yun YP, Propionibacterium acnes, Arch. Pharm. Res., 42(1), 89-94 (1998).
  12. Mikamia E, Goto T, Ohno T, Matsumoto H, Nishid M, J. Pharm. Biomed. Anal., 28(2), 261 (2002)
  13. Zhang JP, Chen QX, Song KK, Xie JJ, Food Chem., 95, 579 (2006)
  14. Carey DE, McNamara PJ, Front. Microbiol., 5, 1 (2015)
  15. Kim NH, Mun SJ, Kim AH, Min JH, Ahn JH, Ha WH, Kim BI, J. Korean Acad. Oral Health, 35(1), 10 (2011)
  16. Aiell AE, Larson EL, Levy SB, Clin. Infect. Dis., 45, 137 (2007)
  17. Elshikh M, Moya-Ramirez I, Moens H, Roelants S, Soetaert W, Marchant R, Banat IM, J. Appl. Microbiol., 123(5), 1111 (2017)
  18. Hu Y, Ju LK, J. Biotechnol., 87, 263 (2001)
  19. Kim HS, Kim YB, Lee BS, Kim EK, J. Microbiol. Biotechnol., 15(1), 55 (2005)
  20. Cho WG, Park HS, Ahn BJ, J. Soc. Cosmet. Sci. Korea, 34(4), 317 (2008)
  21. Farhadieh B, J. Pharm. Sci., 62(10), 1685 (1973)